Aphria Inc.
TSX VENTURE : APH
OTCQB : APHQF

Aphria Inc.

September 19, 2016 08:15 ET

Aphria Finalizes Licensing Deal With Tokyo Smoke

TORONTO, ONTARIO--(Marketwired - Sept. 19, 2016) - Aphria Inc. ("Aphria") (TSX VENTURE:APH)(OTCQB:APHQF), in connection with its previously announced licensing deal with Tokyo Smoke, a premium cannabis-oriented lifestyle brand, has issued to Tokyo Smoke 38,759 common shares of Aphria and 200,000 common share purchase warrants exercisable for a period of 5 years at an exercise price of $3.14 per warrant. The warrants will be held in escrow subject to the achievement of certain sales thresholds. The agreement and the issuance of the aforementioned securities have been conditionally approved by the TSXV.

About Tokyo Smoke

Tokyo Smoke is an award-winning lifestyle brand that brings sophistication and design to coffee, clothing and cannabis. Founded by father and son, Lorne and Alan Gertner, Tokyo Smoke is based on a strong passion for design and strong desire to elevate the cannabis landscape. Located in Toronto, Ontario, the brand's flagship location, Tokyo Smoke Found, launched in April 2015. Tokyo Smoke will expand its retail and recreational cannabis presence into the United States in 2017.

About Aphria Inc.

Aphria Inc., one of Canada's leading Licenced Producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria produces, supplies and sells medical cannabis. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. The company is committed to providing pharma-grade medical cannabis and superior patient care while balancing patient economics and returns to shareholders.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "will" "should", "anticipate", "expect", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to internal expectations, any commentary related to the legalization of marijuana and the timing related thereto, expectations with respect to the availability of products and expectations regarding Health Canada and other regulatory approvals. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange (the "Exchange") nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Aphria Inc.
    Vic Neufeld
    President & CEO
    1-844-427-4742